|

Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis

RECRUITINGN/ASponsored by Azienda Socio Sanitaria Territoriale della Valle Olona
Actively Recruiting
PhaseN/A
SponsorAzienda Socio Sanitaria Territoriale della Valle Olona
Started2023-10-09
Est. completion2024-07-18
Eligibility
Age18 Years – 95 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06017739

Summary

The aim of the study is to compare the efficacy of using EFA technology versus the combination of EFA + high flow in hypersecretory patients COPD and bronchiectasis

Eligibility

Age: 18 Years – 95 YearsHealthy volunteers accepted
Inclusion Criteria:

* COPD diagnosed by spirometry
* Bronchiectasis diagnosed by CT
* 2 Exacerbation/year

Exclusion Criteria:

* Cystic Fibrosis
* OSAS
* Non Invasive Ventilation
* Ineffective Cough
* Exacerbation in progress
* Hemodynamic Instability
* severe heart failure

Conditions2

Bronchiectasis AdultCOPD

Browse More Trials

COPD trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.